Abstract: The present disclosure provides various insights relating to treatment of viral infection with soluble ACE2 variants, specifically including soluble human ACE2 (hACE2) variants. For example, the present disclosure teaches that decoy activity, which may intercept virus-receptor interactions, and ACE2 enzymatic activity can provide separate contributions to therapeutic efficacy; among other things, the present disclosure provides particular therapeutic regimens (e.g., relating to treatment of particular patient populations and/or to dosing regimens, combination therapies, etc.) for certain soluble ACE2 variants. Still further, the present disclosure provides certain particular ACE2 variants and methods of making and/or using them, including in accordance with particular therapeutic regimens.

Abstract: The preparation method of a starch-based double-loaded functional nanoparticle includes: performing restrictive hydrolysis treatment on egg high-density lipoprotein using proteases to obtain the polypeptide; performing self-assembling on a mixed system containing the polypeptide and quercetin under the alkaline condition to form a micelle nanoparticle; performing covalent grafting reaction on a mixed system containing the micelle nanoparticle and anthocyanin under the alkaline condition to form a graft; and electrostatically compounding carboxymethyl dextrin with the graft to obtain the starch-based double-loaded functional nanoparticle. In the preparation method, raw materials derived from natural sources are used, and the self-assembled colloid nanoparticle with good properties can be obtained by adjusting the pH without any organic reagents.

Abstract: Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols.

Abstract: A biocompatible material for securing such implantable medical devices, for example by using an adhesive path.

Abstract: A polymer-based material includes a polymeric binder and one or more porous active materials that adsorb, chemisorb, decompose, or a combination thereof, a hazardous chemical. The polymeric binder and the one or more porous active materials are combined to form a composite bead. The polymeric binder may include a polyurethane or a styrene-based block copolymer. The porous active materials may comprise metal-organic frameworks, metal oxides, metal hydroxides, and metal hydrates. The one or more porous active materials may be between 1 and 99 wt % of a total composite mass of the composite bead. Alternatively, the one or more porous active materials may be between 80 and 95 wt % of a total composite mass of the composite bead. The hazardous chemical may include a chemical warfare agent, a simulant of chemical warfare agents, and toxic industrial chemicals.

Abstract: Methods are disclosed for the reduction or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms using compositions comprising a synergistic combination of thermolysin and at least one aminoglycoside antibacterial agent.

Abstract: A system and method for treating a tissue is provided. The treatment causes a tightening or lifting of tissue. The method includes delivering a photochemical agent through a depth of the tissue to distribute the photochemical agent adjacent proteins within the tissue and irradiating the tissue with an electromagnetic irradiation at a wavelength that activates the photochemical agent, causing a protein response that brings fibers of the tissue closer together in order to one of reduce tissue laxity and tighten the tissue. A kit is provided to facilitate the method.

Abstract: This invention relates generally to a method of inhibiting epithelial cell proliferation including the treatment of conditions associated with aberrant epithelial cell proliferation in mammals, including animals and humans. The present invention is particularly relevant for the treatment of cancer.

Abstract: Methods and compositions using trehalose or a derivative or prodrug thereof for treating pre-eclampsia in a subject are disclosed.

Abstract: The present invention relates to a method for diagnosing or pre-diagnosing a disease associated with podocyte foot process effacement in a subject or for determining the risk of a subject to develop a disease associated with podocyte foot process effacement, said method comprising the steps of a) determining the length of the slit diaphragm (ISD) formed by podocyte foot processes in a specific area A in a renal tissue sample of said subject by super resolution light microscopy; b) comparing the length of the slit diaphragm (ISD) formed by podocyte foot processes in a specific area A as determined in step (a) with the length of the slit diaphragm (ISD) formed by podocyte foot processes in a comparable specific area A in a renal tissue sample of a subject who at the time of the sampling showed no clinical symptoms of a disease associated with podocyte foot process effacement, wherein a deviation indicates a disease associated with podocyte foot process effacement.

Abstract: An enzymatic extraction agent, as well as methods, compositions and kits for detecting Group A Streptococcus in a biological sample, which involve the enzymatic agent, are described.

Abstract: An oral composition comprising at least one probiotic bacteria selected from the genera: Lactobacillus, Bifidobacterium, and Bacillus, and ferric pyrophosphate.

Abstract: Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.

Abstract: The invention relates to placenta-derived matrix, methods of preparing, and methods of use thereof. The invention also relates to methods of culturing cells, delivering cells, promoting differentiation of stem cells or tissue-specific progenitor cells, and repairing, replacing, regenerating, filling, reducing or inhibiting scarring of defects using the same. The invention further relates to methods of coating placenta-derived matrix on a surface or injecting the placenta-derived matrix into a site of interest.

Abstract: A method is disclosed for making palatable methionine-restricted foods, to deliver a methionine-restricted diet to human or veterinary patients. A protein or a food product containing protein is partially oxidized, preferably with ozone, to oxidize nearly all of the methionine and cysteine. After oxidation, tryptophan and lysine are optionally added back since they tend to be oxidized also. Optionally, a small amount of methionine is also added back so that the final methionine is within a preferred range of about 0.85 to about 1.8 gram methionine per 100 gram total protein, preferably about 1.2 gram per 100 gram total protein.

Abstract: The present invention provides therapeutic products with decreased fibrinolytic activity of t-PA-deficient and/or plasminogen-deficient blood products, as well as compositions, kits and methods using the same in treating bleeding associated with hereditary or acquired bleeding disorders. The invention further provides extracorporeal apparatus for blood or blood products Plasmapheresis aimed to prevent or treat bleeding disorders.

Abstract: A composition for mitigating, treating, and/or preventing symptoms associated with veisalgia. In one embodiment the composition comprises one or more ingredients selected from the group consisting of: dihydromyricetin, N-acetyl cysteine, salicin, quercetin, bromelain, opuntia, potassium, sodium, magnesium, B-vitamins, vitamin C, taurine, caffeine, monk fruit, turmeric, curcumin, ginger root, and black pepper extract. A method for treating symptoms associated with veisalgia is also described. In one embodiment, the composition is administered in liquid or pill form.

Abstract: The invention relates to a lactic acid bacterium (LAB), Lactobacillus fermentum PS150, and a bioactive protein produced by the LAB, which has an advantageous effect in improving mood disorder, enhancing cognitive functions in brain and treating or preventing a neurodegenerative disease.

Abstract: Methods are disclosed for the reduction or elimination of bacterial biofilms on biological and non-biological surfaces, as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms using compositions comprising a synergistic combination of thermolysin and at least one aminoglycoside antibacterial agent.

Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of Celiac Disease. Also described herein is a method for treating a subject with Celiac Disease using digestive enzymes and their derivatives to alleviate the symptoms of Celiac Disease. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of Celiac Disease.

Abstract: Autologous anti-cancer vaccines and methods of manufacture and treatment are provided, including expansion of individual patient-derived tumor cells in an immune-compromised animal(s) to attain, quantitatively and qualitatively, sufficient material for efficacious vaccine production and utilization, to elicit an immune response against micrometastases and/or recurrence in the individual patient following tumor excision.

Abstract: The present invention relates to the effect of plasminogen in the treatment and/or elimination of angiocardiopathy, especially angiocardiopathy caused by diabetes mellitus, thereby providing a new strategy for treating different kinds of angiocardiopathy, especially angiocardiopathy and its related disorders caused by diabetes mellitus.

Abstract: Disclosed herein are methods and compositions useful for evaluating, selecting, identifying, or making a cell or cell line that has improved production capacity for generating higher yields of products and/or improved capacity to produce higher quality products. Products, as described herein, can include a polypeptide that is endogenously expressed by the cell, a recombinant polypeptide that is not endogenously expressed, or a non-naturally occurring recombinant polypeptide. The methods described herein include modulating, e.g., inhibiting, the protein degradation pathway by using a proteasome inhibitor, an ER-associated degradation (ERAD) inhibitor, or a ubiquitin pathway inhibitor.

Abstract: Hydroxycitric acid-metal heterocyclic compounds with covalent characteristics are provided. The subject hydroxycitric acid compounds include monomeric hydroxycitric acid (HCA) compounds having a divalent metal, lactone forms thereof, and dimeric compound forms thereof. The monomeric HCA compound includes a divalent metal (X) bonded via a 5-membered ring to both the carboxylic acid and the hydroxy group of the central C2 carbon of the HCA. In addition, a monovalent metal (Y) can also be bonded to the carboxylic acid of C3 or C1, or to both C1 and C3. The subject dimeric compounds include monomeric HCA compounds linked via a second divalent metal (X) to a carboxylic acid group of each HCA unit at C3 or C1. Also provided are compositions including a monomeric HCA compound and one or more other additional compounds. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided.

Abstract: The present invention concerns a method for selectively activating a thermostable hydrolase at a temperature above T1. The present invention provides compositions comprising a thermostable hydrolase and a temperature sensitive inhibitor, wherein said thermostable hydrolase and said temperature sensitive inhibitor form a hydrolase-inhibitor complex at a temperature below T1, but which dissociates at a temperature of about T1. The present invention also relates to uses of said compositions, and a method for preparing said compositions.

Abstract: The disclosure relates, in general, to Glycogen Storage Disease Type VI and, in particular, to a method of treating Glycogen Storage Disease Type VI and to compounds and compositions suitable for use in such a method.

Abstract: The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.

Abstract: This disclosure relates to growth media and environments for in vitro culturing of cells that produce or are capable of producing antibodies. In certain embodiments, the media comprises IL-6, fibronectin, and typically a saccharide. In certain embodiments, the disclosure contemplates cell culture compositions comprising IL-6 and fibronectin that are derived from proteins secreted from mesenchymal stromal/stem cells (MSCs). In certain embodiments, the disclosure contemplates enclosures comprising culture compositions disclosed herein that are in ambient air or optionally in an environment wherein oxygen is absent or at a low concentration.

Abstract: The present disclosure provides compositions which may be used to augment, supplement and/or replace the products of certain UV sensitive/dependent processes. In particular, the disclosure provides sunscreen compositions which avoid problems associated with prior art sunscreen compositions which inhibit the natural progression of certain in vivo sunlight/UV dependent processes including processes which result in Nitric Oxide/Vitamin D production in the skin.

Abstract: The present invention relates to a method for the recombinant production of a serine protease comprising (a) culturing a host cell comprising one or more vectors, wherein the one or more vectors encode in expressible form the serine protease and a proteinaceous inhibitor of the serine protease, wherein the proteinaceous inhibitor of the serine protease is heterologous with respect to the serine protease, under conditions wherein the serine protease and the proteinaceous inhibitor of the serine protease are expressed; or (a?) culturing a host cell the genome of which encodes in expressible form the serine protease and a proteinaceous inhibitor of the serine protease, wherein the proteinaceous inhibitor of the serine protease is heterologous with respect to the serine protease, and wherein the coding sequences of the serine protease and/or the proteinaceous inhibitor have been introduced into the host cell genome by applying a CRISPR technology, under conditions wherein the serine protease and the proteinaceous

Abstract: Tissue repair and restoration can be performed using an elastic material formed from tropoelastin. The elastic material can be formed by providing a solution of tropoelastin monomers, applying the solution to a surface, and heating the solution on the surface in absence of a cross-linking agent to enable the tropoelastin monomers to bind to each other to form an elastic material that does not dissociate into tropoelastin monomers when the elastic material is contacted with an aqueous solution.

Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.

Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

Abstract: A method is disclosed for making palatable methionine-restricted foods, to deliver a methionine-restricted diet to human or veterinary patients. A protein or a food product containing protein is partially oxidized, preferably with ozone, to oxidize nearly all of the methionine and cysteine. After oxidation, tryptophan and lysine are optionally added back since they tend to be oxidized also. Optionally, a small amount of methionine is also added back so that the final methionine is within a preferred range of about 0.85 to about 1.8 gram methionine per 100 gram total protein, preferably about 1.2 gram per 100 gram total protein.

Abstract: The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.

Abstract: The present invention relates to the use of plasminogen in the treatment of cervical erosion. Compared to other existing drugs for treating cervical erosion, the plasminogen or plasmin of the present invention can promote the inflammatory repair of damaged mucosa. Therefore, plasminogen may become a novel strategy to treat cervical erosion.

Abstract: Embodiments of the present invention are directed to the administration of bryostatins and bryostatins and retinoids for the treatment of disease responsive to increases in alpha secretase activity. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes, cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and opthalmic diseases such as glaucoma.

Abstract: The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognised and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides.

Abstract: A composition and a method to improve the exploit of oil from a hydrocarbon containing formation are disclosed. The method is characterized in that a aqueous composition including extract of a plant is injected into the formation to reduce the interfacial tension between the oil trapped in the formation and water, and the oil in said aqueous mixture is recovered for further use. Preferably, the aqueous mixture injected comprises an interfacial tension reducing composition made from a plant extract based on a plant family to which the plants Ziziphus Spina Christi and Aloe Vera belong. In particular the injection mixture also comprises at least one of the following constituents: fructose, sucrose, maltose, proteins, lipids and saponins.

Abstract: The present invention relates to the effect of plasminogen in the prevention or treatment of retinopathy caused by diabetes mellitus, thereby providing a new therapeutic strategy for treating different types of diabetes mellitus-related retinopathy.

Abstract: This document relates to molecular complexes having acid alpha glucosidase activity and at least one modification that results in enhanced ability of the molecular complex to be transported to the interior of a mammalian cell.

Abstract: An anti-endotoxin polypeptide is provided. The anti-endotoxin polypeptide having the formula (I) A1-L-C1, wherein A1 and C1 independently is a short peptide with ?-helix, L is AGP (Ala-Gly-Pro) or a peptide bond, and the hydrophobicity of the hydrophobic terminus in the anti-endotoxin polypeptide is between about 0.425 and 0.765. The anti-endotoxin polypeptide of the invention can neutralize the lipopolysaccharide and has the low hemolysis and high salt resistance, simultaneously. The present invention also provides a method for design an anti-endotoxin polypeptide, the anti-endotoxic activity is adjusted through increasing and/or decreasing hydrophobicity of the hydrophobic terminal end.

Abstract: Disclosed is a combination of two or more lipase enzymes, and its use for treating a lipid digestion deficiency and/or a digestive disorder. At least one lipase enzyme has a pH optimum at an acidic pH value, while at least one other lipase enzyme has a pH optimum at an alkalic pH value.

Abstract: The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base.

Abstract: The present invention concerns a method for selectively activating a thermostable hydrolase at a temperature above T1. The present invention provides compositions comprising a thermostable hydrolase and a temperature sensitive inhibitor, wherein said thermostable hydrolase and said temperature sensitive inhibitor form a hydrolase-inhibitor complex at a temperature below T1, but which dissociates at a temperature of about T1. The present invention also relates to uses of said compositions, and a method for preparing said compositions.

Abstract: The present invention relates to a novel process of isolating and purifying tissue plasminogen activator and its variants more specifically TNK-tPA from CHO cells and describes an industrially applicable, simple, cost effective, robust and highly efficient process of TNK-tPA purification.

Abstract: The present invention relates to a polypeptide having proline-specific endoprotease activity, selected from the group consisting of i. a polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 2; ii. a polypeptide that has least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the mature polypeptide sequence of SEQ ID NO: 2; iii. a polypeptide encoded by a nucleic acid that hybridizes under medium stringency, preferably under high stringency conditions to the complementary strand of the mature polypeptide coding sequence of SEQ ID NO:1; iv. a polypeptide encoded by a nucleic acid that has at least 70%, 75% 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the mature polypeptide coding sequence of SEQ ID NO: 1. The invention further relates to a method of producing the polypeptide and a process for the preparation of a food or feed product wherein the polypeptide is used.

Abstract: Described herein are methods and genetically engineered cells useful for uncapping a mannose-6-phosphate residue on an oligosaccharide.

Abstract: Provided herein are methods of adjusting or selecting a gluten peptide therapy based on the human leukocyte antigen (HLA) genotype, in particular HLA-DQ2.5 homozygosity, of a subject having or suspected of having Celiac disease. Also provided herein are methods of identifying (e.g., diagnosing) a subject, such as a subject having or suspected of having Celiac disease and/or assessing the efficacy of treatment of Celiac disease, e.g. by determining responsiveness to a therapeutic gluten peptide composition or cytokine response, and kits relating thereto.

Abstract: Systems, methods, and computer readable media for diagnosing or characterizing a genetic predisposition to develop cancer are provided. Nucleic acids comprising a germline nucleic acid sequence encoding the BRCA1 associated protein 1 are sequenced or probed to determine if the nucleic acid sequence includes alterations that predispose a subject to develop cancer.